Onconetix Holds Annual Stockholder Meeting

• Onconetix shareholders on November 10, 2026 approved issuing up to 154,856,150 common shares upon conversion of Series F Preferred Stock.
• The board received authority to execute a 1-for-2 to 1-for-15 reverse stock split within one year, choosing the final ratio.
• Josh Epstein was elected as a Class II director.
• Shareholders ratified MaloneBailey as independent auditor for the fiscal year ending December 31, 2026.
• Adjournment to solicit additional proxies, if needed to secure proposal approvals, was also authorized.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-118266), on November 12, 2026, and is solely responsible for the information contained therein.